Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Emerg Infect Dis ; 30(5): 1004-1008, 2024 May.
Article in English | MEDLINE | ID: mdl-38666640

ABSTRACT

We evaluated the in vitro effects of lyophilization for 2 vesicular stomatitis virus-based vaccines by using 3 stabilizing formulations and demonstrated protective immunity of lyophilized/reconstituted vaccine in guinea pigs. Lyophilization increased stability of the vaccines, but specific vesicular stomatitis virus-based vaccines will each require extensive analysis to optimize stabilizing formulations.


Subject(s)
Disease Models, Animal , Freeze Drying , Vesicular Stomatitis , Viral Vaccines , Animals , Guinea Pigs , Viral Vaccines/immunology , Viral Vaccines/administration & dosage , Vesicular Stomatitis/immunology , Vesicular Stomatitis/prevention & control , Vesicular Stomatitis/virology , Vesiculovirus/immunology , Vesiculovirus/genetics , Antibodies, Viral/immunology , Antibodies, Viral/blood , Vaccine Efficacy , Vesicular stomatitis Indiana virus/immunology
2.
Emerg Infect Dis ; 29(4): 858-860, 2023 04.
Article in English | MEDLINE | ID: mdl-36878011

ABSTRACT

The global spread of monkeypox virus has raised concerns over the establishment of novel enzootic reservoirs in expanded geographic regions. We demonstrate that although deer mice are permissive to experimental infection with clade I and II monkeypox viruses, the infection is short-lived and has limited capability for active transmission.


Subject(s)
Monkeypox virus , Mpox (monkeypox) , Animals , Monkeypox virus/genetics , Mpox (monkeypox)/epidemiology , Peromyscus , North America/epidemiology
3.
Viruses ; 15(3)2023 03 17.
Article in English | MEDLINE | ID: mdl-36992478

ABSTRACT

Nigeria experiences annual outbreaks of Lassa fever (LF) with high case numbers. At least three clades of Lassa virus (LASV) have been documented in Nigeria, though recent outbreaks are most often associated with clade II or clade III viruses. Using a recently isolated clade III LASV from a case of LF in Nigeria in 2018, we developed and characterized a guinea pig adapted virus capable of causing lethal disease in commercially available Hartley guinea pigs. Uniform lethality was observed after four passages of the virus and was associated with only two dominant genomic changes. The adapted virus was highly virulent with a median lethal dose of 10 median tissue culture infectious doses. Disease was characterized by several hallmarks of LF in similar models including high fever, thrombocytopenia, coagulation disorders, and increased inflammatory immune mediators. High viral loads were noted in all solid organ specimens analyzed. Histological abnormalities were most striking in the lungs and livers of terminal animals and included interstitial inflammation, edema, and steatosis. Overall, this model represents a convenient small animal model for a clade III Nigeria LASV with which evaluation of specific prophylactic vaccines and medical countermeasures can be conducted.


Subject(s)
Lassa Fever , Viral Vaccines , Guinea Pigs , Animals , Lassa virus , Nigeria/epidemiology , Antibodies, Viral
4.
Sci Transl Med ; 14(673): eade7646, 2022 11 30.
Article in English | MEDLINE | ID: mdl-36318038

ABSTRACT

The recent emergence of the monkeypox virus (MPXV) in non-endemic countries has been designated a Public Health Emergency of International Concern by the World Health Organization. There are currently no approved treatments for MPXV infection in the United States or Canada. The antiviral drug tecovirimat (commonly called TPOXX), previously approved for smallpox treatment, is currently being deployed for treatment of MPXV infections where available based on previously accrued data. We tested the efficacy of TPOXX both in vitro and in vivo against a clade 2 Canadian 2022 isolate of MPXV isolated during the current outbreak. TPOXX prevented MPXV replication in vitro with an effective concentration in the nanomolar range. To evaluate TPOXX efficacy in vivo, we first characterized the CAST/EiJ mouse model with the same 2022 Canadian isolate. Unlike previous descriptions of this model, the Canadian isolate was not lethal in CAST/EiJ mice, although it replicated efficiently in the respiratory tract after intranasal infection. Subsequent experiments demonstrated that daily oral TPOXX treatment markedly reduced viral titers in the tissues 1 and 2 weeks after infection. Our data indicate that TPOXX is highly effective against currently circulating MPXV strains and could be an important contributor to curbing the ongoing outbreak.


Subject(s)
Monkeypox virus , Mpox (monkeypox) , Mice , Animals , Canada , Mpox (monkeypox)/drug therapy , Mpox (monkeypox)/prevention & control , Isoindoles/pharmacology , Isoindoles/therapeutic use
5.
MicroPubl Biol ; 20222022.
Article in English | MEDLINE | ID: mdl-35783574

ABSTRACT

A circulating tumor cell (CTC) is a type of cell that is shed from solid tumors, swept away in the bloodstream or lymphatic system, and has the potential to cause tumorigenesis at a secondary location. Here we describe an early pupal leg system to study CTCs in vivo and to compare the CTCs described in this work to those previously studied in vitro. We quantified cellular parameters such as the number, size, and shape of CTCs, and our findings are consistent with previous in vitro studies. Thus, live imaging of CTCs in model organisms can complement and validate previous work in this field and can be an initial step when deciphering how in vivo CTCs behave in humans during metastasis.

SELECTION OF CITATIONS
SEARCH DETAIL
...